Abstract #4058

Longitudinal Changes in Magnetic Resonance Spectroscopy Over 96 Weeks in Relapsing MS Treated with Ocrelizumab versus Interferon Beta-1a

Erin L MacMillan¹, Julia J Schubert¹, Irene M Vavasour^1,2, Roger Tam², Alexander Rauscher², Rick White³, Hideki Garren⁴, David Clayton⁴, Victoria Levesque⁴, David KB Li², Anthony L Traboulsee¹, and Shannon H Kolind¹

¹Neurology, University of British Columbia, Vancouver, BC, Canada, ²Radiology, University of British Columbia, Vancouver, BC, Canada, ³Statistics, University of British Columbia, Vancouver, BC, Canada, ⁴Genetech, Roche Pharmaceuticals, South San Francisco, CA, United States

Single voxel magnetic resonance spectroscopy (MRS) was performed in thirty-seven relapsing multiple sclerosis (MS) patients, who were enrolled in a phase III clinical trial of ocrelizumab versus interferon beta-1a, at baseline, 24, 48, and 96 weeks follow-up. 24 healthy controls were also scanned. MRS demonstrated a significant interaction between visit and treatment group in the NAA/tCr ratio. The change in absolute metabolite concentrations over 96 weeks revealed that this interaction was primarily driven by increased NAA and reduced inflammation in the ocrelizumab group, while the interferon beta-1a group exhibited a smaller increase in NAA and ongoing inflammation.

This abstract and the presentation materials are available to members only; a login is required.

Join Here